Sun.Aug 18, 2024

article thumbnail

Expert: Diabetes Initiatives Led by Community Pharmacists, Students Drive Treatment Innovation

Pharmacy Times

Jon Easter talks about community pharmacy's role in propelling diabetes innovation and optimizing patient care.

article thumbnail

Weekend ICYMI: August 12 to August 16

Drug Topics

In case you missed it, this week we had news about digital therapeutics for depression, bracing for fall allergies, at-home tests for sexually transmitted infections, and more.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pfizer grows digital team with chief AI officer appointment

pharmaphorum

Pfizer has appointed Berta Rodriguez-Hervas to its digital leadership team, naming her chief artificial intelligence and analytics officer

108
108
article thumbnail

Translating Diabetes Interventions into Sustainable Programs in Community Pharmacy

Drug Topics

Pharmacists need support—through partnerships and reimbursement—to provide more diverse services to patients.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Highlight: How The NACDS Foundation Promotes Research, Change in Pharmacy

Pharmacy Times

Sara Roszak discusses her role as president of the NACDS Foundation.

139
139
article thumbnail

IQVIA: GLP-1 Therapies, Health Care Cyber Attacks Among Top Industry Impacts in 2024

Drug Topics

Perhaps unsurprisingly, GLP-1 therapies are expected to continue making headlines within the industry.

123
123

More Trending

article thumbnail

Interview: 3 Key Components Crucial for Sustainable Health Care Models

Drug Topics

Sustainable health care models require buy-in from multiple stakeholders, including pharmacists, payers, and patients.

98
article thumbnail

Long Time Passing: Where Have All the De Novo Decision Summaries Gone?

The FDA Law Blog

By Véronique Li, Senior Medical Device Regulation Expert & Jeffrey N. Gibbs — In 1997, Congress wisely amended the Federal Food, Drug, and Cosmetic Act (FDCA) by adding Section 513(f)(2) to establish the De Novo process. The De Novo process provides a regulatory pathway to classify novel devices for which general controls alone or general and special controls provide reasonable assurance of safety and effectiveness for the intended use.

FDA 69
article thumbnail

Transforming Diabetes Interventions Into Sustainable Programs for Pharmacy

Drug Topics

To scale up diabetes intervention programs, sustainable workflows, trainings, and payment models are key.

98
article thumbnail

Experimental Malaria Vaccine Found Safe in Multiple Trials in Mali

BioPharm

National Institutes of Health’s National Institute of Allergy and Infectious Diseases collaborated with the University of Sciences, Techniques and Technologies of Bamako, Mali to conduct the trials.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Omeprazole for cats: Dosage and safety

The Checkup by Singlecare

Omeprazole is a stomach acid reducer. Most people are familiar with it as the brand name heartburn drug Prilosec OTC. It works by blocking the stomach’s acid production, reducing irritation and erosion of the stomach lining. Veterinarians use it off-label in cats to treat ulcers or acid irritation and erosion of the esophagus (esophagitis). Veterinarians rarely encounter stomach ulcers in cats, but esophagitis is a more common problem usually caused by acid reflux.

Dosage 52
article thumbnail

2024 Acne Guidelines – Top 5 Takeaways

Med Ed 101

The American Academy of Dermatology released guidelines for the treatment of acne in early 2024. As I’m updating study materials, I thought I’d share a sneak peek of my top 5 takeaways from the 2024 Acne Guidelines. Retinoids and Benzoyl Peroxide In mild to moderate acne, topical retinoids will be a first-line consideration with benzoyl […] The post 2024 Acne Guidelines – Top 5 Takeaways appeared first on Med Ed 101.

52
article thumbnail

Furosemide for cats: Dosage and safety

The Checkup by Singlecare

Furosemide is a generic diuretic widely used in veterinary medicine. While it’s used for various conditions in other animals, veterinarians give furosemide to cats as part of a multidrug treatment of congestive heart failure (CHF). Furosemide increases urine production in cats, eliminating excess water that builds up in the lungs, belly, and other tissues due to heart failure.

Dosage 52
article thumbnail

5 health issues to watch for at the Democratic National Convention

STAT

WASHINGTON — Democrats have set the stage for a convention this week packed with boasts about some of their most popular health care policy wins and future moonshot goals. The four-day event in Chicago will kick off as former President Trump increases attacks on rising inflation, economic hardship, and border control policies under the Biden administration.

125
125
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.